DK3506904T3 - Behandling af demens - Google Patents
Behandling af demens Download PDFInfo
- Publication number
- DK3506904T3 DK3506904T3 DK17761842.8T DK17761842T DK3506904T3 DK 3506904 T3 DK3506904 T3 DK 3506904T3 DK 17761842 T DK17761842 T DK 17761842T DK 3506904 T3 DK3506904 T3 DK 3506904T3
- Authority
- DK
- Denmark
- Prior art keywords
- dementia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Valve Device For Special Equipments (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3506904T3 true DK3506904T3 (da) | 2021-01-04 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17761842.8T DK3506904T3 (da) | 2016-09-01 | 2017-08-25 | Behandling af demens |
Country Status (18)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104529939B (zh) | 2006-03-29 | 2019-05-07 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| PT2057136E (pt) | 2006-07-11 | 2013-08-28 | Wista Lab Ltd | Processos de síntese e/ou purificação de compostos diaminofenotiazínio |
| EP3487505B1 (en) | 2016-07-25 | 2023-05-03 | WisTa Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
| MX2021000894A (es) * | 2018-07-26 | 2021-03-31 | Wista Lab Ltd | Dosificacion optimizada de diaminofenotiazinas en poblaciones. |
| JP7401531B2 (ja) | 2018-09-05 | 2023-12-19 | ゲンティング タークス ダイアグノースティク センター エスディエヌ ビーエイチディ | 神経変性疾患のためのネットワーク法 |
| GB201909493D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| AU2021268465A1 (en) * | 2020-05-05 | 2022-12-08 | TauRx Therapeutics Management Ltd | Methylthioninium compounds for use in the treatment of hypoxemia |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| US20240300940A1 (en) * | 2023-02-21 | 2024-09-12 | Prosetta Biosciences, Inc. | Phenothiazinyl Compounds and Uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| DE60324788D1 (de) * | 2002-05-31 | 2009-01-02 | Lundbeck & Co As H | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit |
| PL2322517T3 (pl) | 2004-09-23 | 2019-09-30 | Wista Laboratories Ltd. | Sposoby syntezy chemicznej i oczyszczania związków diaminofenotiazyniowych, w tym chlorku metylotioniny (MTC) |
| EP2853293B1 (en) * | 2006-03-29 | 2017-11-22 | WisTa Laboratories Ltd. | Thioninium compounds and their use |
| CN104529939B (zh) | 2006-03-29 | 2019-05-07 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| PT2057136E (pt) | 2006-07-11 | 2013-08-28 | Wista Lab Ltd | Processos de síntese e/ou purificação de compostos diaminofenotiazínio |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| PL2167095T3 (pl) * | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
| CA2701075C (en) | 2007-10-03 | 2019-02-12 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines. |
| PT3792254T (pt) | 2009-09-24 | 2023-10-19 | Wista Lab Ltd | Hidratos de cloreto de metiltionínio cristalino |
| MY161463A (en) | 2009-09-24 | 2017-04-14 | Wista Lab Ltd | Process for the preparation of substantially pure methylthionium chloride pentahydrate form a |
| JP5898701B2 (ja) * | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active Active
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/hr unknown
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 MX MX2019002429A patent/MX384442B/es unknown
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3506904B1 (en) | 2020-12-09 |
| SG11201901125TA (en) | 2019-03-28 |
| EP3506904A1 (en) | 2019-07-10 |
| CN109890391A (zh) | 2019-06-14 |
| SI3506904T1 (sl) | 2021-03-31 |
| CA3034625A1 (en) | 2018-03-08 |
| CN109890391B (zh) | 2023-01-31 |
| HRP20210162T1 (hr) | 2021-03-19 |
| PL3506904T3 (pl) | 2021-07-26 |
| KR20190045273A (ko) | 2019-05-02 |
| MY187564A (en) | 2021-09-30 |
| KR102559354B1 (ko) | 2023-07-26 |
| PT3506904T (pt) | 2021-02-02 |
| JP2019526571A (ja) | 2019-09-19 |
| WO2018041739A1 (en) | 2018-03-08 |
| JP7066679B2 (ja) | 2022-05-13 |
| MX2019002429A (es) | 2019-07-08 |
| AU2017318333A1 (en) | 2019-04-18 |
| GB201614834D0 (en) | 2016-10-19 |
| US10842796B2 (en) | 2020-11-24 |
| ES2847929T3 (es) | 2021-08-04 |
| AU2017318333B2 (en) | 2023-05-11 |
| MX384442B (es) | 2025-03-14 |
| US20190192530A1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3506904T3 (da) | Behandling af demens | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3318115T3 (da) | Maskine til behandling af svinegylle | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK2897382T3 (da) | Forbedring af binaural kilde | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
| DK3532076T3 (da) | Immunterapeutiske behandlinger af tumorer | |
| IL313083A (en) | Terlipressin compositions and their methods of use | |
| DK3113773T3 (da) | Krystallinske former af grapiprant | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3201323T3 (da) | Modificering af bakteriofag | |
| DK3529236T3 (da) | Krystalformer af eravacyclin |